

Appl. No. 09/934,025
Amdt. dated February 14, 2005
Reply to Office Action of November 12, 2004

PATENT

Amendments to the Specification

Please replace the paragraph on page 2, lines 21-23 with the following amended paragraph:

In one aspect, the present invention provides a monoclonal antibody that specifically binds to modified β -tubulin, the antibody selected from the group consisting of 1F6D8, 1B2C11, 3A1C11, 2C1H7, 3F2A4, 5F5C11, and 6D4D11. The hybridoma cell line 2C1H7, Accession number, PTA-2686, was deposited on November 16, 2000 with American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110, USA.